drugset / Trial / NCT02092181

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

NCT02092181

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in people with Parkinson's Disease.

Timeline

Start
2014-03
Primary completion
2018-07-01
Completion
2018-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 50 mg Oral

Indications